Clinical Trial Update: Camrelizumab Plus R-CHOP Regimen in Untreated Primary Extranodal DLBCL [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating camrelizumab plus R-CHOP in untreated primary extranodal diffuse large B-cell lymphoma (DLBCL).

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Diffuse Large B-cell Lymphoma
• Extranodal Lymphoma

Drugs mentioned

• Camrelizumab (camrelizumab)
• R-CHOP

Snippet

Sponsor: Sun Yat-sen University | Conditions: Primary Extranodal Lymphoma, DLBCL | Phase 2 | Status: UNKNOWN